Frequently Asked Questions about Repligen Corporation (RGEN)

Name: Repligen Corporation (RGEN) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Repligen Corporation (RGEN) do?

Accepted Answer

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography r...

Question 2

Is Repligen Corporation (RGEN) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of RGEN reveals an Altman Z-Score of 5.76 and a Piotroski F-Score of 6/9. These metrics, combined with its 5-year revenue trend ($0.74B most recent), help investors decide if RGEN fits their risk profile.

Question 3

What is the current P/E ratio for RGEN?

Accepted Answer

As of the latest trading session, Repligen Corporation (RGEN) has a trailing P/E ratio of 138.47.

Question 4

Who is the CEO of Repligen Corporation?

Accepted Answer

The current Chief Executive Officer of Repligen Corporation is Olivier Loeillot.

Question 5

What was RGEN's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Repligen Corporation reported annual revenues of $0.74B (2025), $0.63B (2024), $0.63B (2023), $0.80B (2022), $0.67B (2021) respectively.

Question 6

Does RGEN pay a dividend?

Accepted Answer

Repligen Corporation does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does RGEN have?

Accepted Answer

In its latest reporting period, Repligen Corporation generated $0.09B in Free Cash Flow against a total debt load of $0.69B.

Question 8

What is the Price-to-Book (P/B) ratio of Repligen Corporation?

Accepted Answer

The Price-to-Book (P/B) ratio for Repligen Corporation (RGEN) is currently 3.21.

Question 9

What is the Price-to-Sales (P/S) ratio of RGEN?

Accepted Answer

Based on trailing twelve-month data, Repligen Corporation (RGEN) trades at a Price-to-Sales (P/S) ratio of 9.14.

Question 10

What is Repligen Corporation's Return on Equity (ROE)?

Accepted Answer

Repligen Corporation (RGEN) has a Return on Equity (ROE) of 2.37%, representing its profitability relative to shareholder equity.

Period	Operating CF	SBC	CapEx	Free CF	True FCF
2025-12	117.4M	32.6M	-23.5M	93.9M	61.3M
2024-12	175.4M	48.1M	-32.9M	142.5M	94.4M
2023-12	113.9M	25.6M	-39M	74.9M	49.4M
2022-12	172.1M	27.3M	-133.3M	38.7M	11.4M
2021-12	119M	27.5M	-71.3M	47.7M	20.2M